Skip to main content

4th International Conference on Bioengineering and Cell Therapy

Friday 7 November 2025
Room E - Faculty of Medicine

Now in its fourth edition, the conference focuses on scientific and clinical advances in the application of cell therapies in regenerative medicine and CAR-T therapies in the field of onco-haematology for immune disorders (rheumatology) and oncology, with a view to the future.

The conference is structured around two scientific sessions:

  • The first session will focus on advances in bioengineering with mesenchymal stem cells and the clinical applications of biocompatible and bioresorbable scaffolds for regenerative therapy of bone/cartilage, skin and cornea.
  • The second session will be dedicated to “CAR-T” (Chimeric Antigen Receptor T cell) therapy, which is an advanced form of “immunotherapy” based on the use of engineered T lymphocytes (from the patient) expressing a specific chimeric receptor directed against a tumour antigen.

The results of the efficacy and safety of CAR-T therapy against certain forms of “aggressive” leukaemia and lymphoma will be presented and discussed, such as: acute lymphoblastic leukaemia (ALL), diffuse large B-cell non-Hodgkin lymphoma (DLBCL), Primary Mediastinal Non-Hodgkin's Lymphoma (PML), Mantle Cell Lymphoma (MCL), Follicular Lymphoma and Multiple Myeloma.

Early and late complications will also be discussed, with particular reference to infectious complications.

Translated with DeepL.com (free version)

For additional informations

Document
Last updated on: